Genelabs Technologies
Biotechnology ResearchView the employees at
Genelabs Technologies-
Jianzhong (John) Zhang Senior RA II at Genelabs Technologies
-
San Diego, California, United States
-
Rising Star
-
Overview
Genelabs is a biopharmaceutical company focused on the discovery and development of novel compounds for infectious diseases. In addition to a late-stage drug candidate for Hepatitis E partnered with GlaxoSmithKline, the company is advancing multiple partnered and proprietary compounds designed to selectively inhibit replication of the hepatitis C virus, targeting the HCV viral proteins - NS5B polymerase, NS4B, and NS5A. In January 2009 Genelabs was bought by GlaxoSmithKline.